Business
Health Canada Approves ARAZLO(TM) (Tazarotene) Lotion, 0.045%, First Such Lotion Treatment For Acne Vulgaris
Health Canada Approves ARAZLO™ (Tazarotene) Lotion, 0.045%, First Such Lotion Trea...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n Health Canada Approves ARAZLO™ (Tazarotene) Lotion, 0.045%, First Such Lotion Treatment For Acne Vulgaris\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Shown to provide strong efficacy with good tolerability profile\n \n \n \n \n LAVAL, QC\n \n ,\n \n Aug. 4, 2021\n \n /CNW Telbec/ - Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) (\"Bausch Health\" or the \"Company\"), and its dermatology division, one of the largest prescription dermatology health care businesses in\n \n Canada\n \n , today announced that Health Canada has approved the Notice of Compliance (NOC) for ARAZLO\n \n TM\n \n (tazarotene) lotion, 0.045%, for the topical treatment of acne vulgaris (common acne) in patients 10 years of age and older.\n \n 1\n \n \n \n \n \n \n \n \n \n \n ARAZLO is the first tazarotene acne treatment available in a lotion formulated with PRISMATREX\n \n TM\n \n technology (a formulation with known hydrating and moisturizers, which may alleviate dryness of skin)\n \n 1\n \n and has been shown to provide strong efficacy with a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment.\n \n \n \n \"Today's approval of ARAZLO showcases our continued commitment to expanding our acne portfolio to help the approximately 5.6 million Canadians who are impacted by this prevalent skin condition,\"\n \n \n \n 2\n \n said Ginette Gagné, Interim President and General Manager,\n \n Bausch Health\n \n , Canada. \"ARAZLO will provide diverse patient populat...